- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07277231
Eine Studie zur Untersuchung von Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) im Vergleich mit Venetoclax plus Acalabrutinib bei Erwachsenen mit zuvor unbehandelter chronischer lymphatischer Leukämie
Eine Phase-3-, Open-Label-, randomisierte Studie von Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) im Vergleich zu Venetoclax plus Acalabrutinib bei Patienten mit zuvor unbehandelter chronischer lymphatischer Leukämie
The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
- Name: Study Director
- Telefonnummer: 8778285568
- E-Mail: clinicaltrials@beonemed.com
Studienorte
-
-
New South Wales
-
Blacktown, New South Wales, Australien, NSW 2148
- Rekrutierung
- Blacktown Cancer and Haematology Centre
-
Concord, New South Wales, Australien, NSW 2139
- Rekrutierung
- Concord Repatriation General Hospital
-
St Leonards, New South Wales, Australien, NSW 2065
- Rekrutierung
- Genesiscare North Shore
-
-
Queensland
-
Woolloongabba, Queensland, Australien, QLD 4102
- Rekrutierung
- Princess Alexandra Hospital
-
-
Victoria
-
Clayton, Victoria, Australien, VIC 3168
- Rekrutierung
- Monash Health
-
Heidelberg, Victoria, Australien, VIC 3084
- Rekrutierung
- Austin Health
-
Malvern, Victoria, Australien, VIC 3144
- Rekrutierung
- Cabrini Hospital Malvern
-
Melbourne, Victoria, Australien, VIC 3004
- Rekrutierung
- The Alfred Hospital
-
-
-
-
-
Brasília, Brasilien, 70390140
- Rekrutierung
- Instituto Dor de Pesquisa E Ensino Distrito Federal
-
Porto Alegre, Brasilien, 90110-270
- Rekrutierung
- Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
-
Salvador, Brasilien, 41950-640
- Rekrutierung
- Ensino E Terapia de Inovacao Clinica Amo Etica
-
São Paulo, Brasilien, 05652-900
- Rekrutierung
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
São Paulo, Brasilien, 01401-004
- Rekrutierung
- Instituto Dor de Pesquisa E Ensino Sao Paulo
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100730
- Rekrutierung
- Peking Union Medical College Hospital
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China, 630014
- Rekrutierung
- The First Affiliated Hospital of Chongqing Medical University
-
-
Fujian
-
Fuzhou, Fujian, China, 350005
- Rekrutierung
- The First Affiliated Hospital of Fujian Medical University
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510555
- Rekrutierung
- Sun Yat Sen University Cancer Center Huangpu Branch
-
Guangzhou, Guangdong, China, 510000
- Aktiv, nicht rekrutierend
- Zhujiang Hospital of Southern Medical University
-
-
Guangxi
-
Nanning, Guangxi, China, 530021
- Rekrutierung
- The First Affiliated Hospital of Guangxi Medical University
-
-
Guizhou
-
Guiyang, Guizhou, China, 550002
- Rekrutierung
- Guizhou Provincial Peoples Hospital
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150000
- Rekrutierung
- Harbin Medical University Cancer Hospital
-
-
Henan
-
Zhengzhou, Henan, China, 450000
- Rekrutierung
- Henan Cancer Hospital
-
-
Hunan
-
Changsha, Hunan, China, 410011
- Rekrutierung
- The Second Xiangya Hospital of Central South University
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Rekrutierung
- Jiangsu Province Hospital
-
Nantong, Jiangsu, China, 201203
- Rekrutierung
- Affiliated Hospital of Nantong University
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- Rekrutierung
- The Second Affiliated Hospital of Nanchang University
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710004
- Rekrutierung
- The Second Affiliated Hospital of Xian Jiaotong University
-
-
Shandong
-
Jinan, Shandong, China, 250000
- Rekrutierung
- Shandong Provincial Hospital
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200025
- Rekrutierung
- Rui Jin Hospital Shanghai Jiao Tong University School of Medicine
-
-
Sichuan
-
Chengdu, Sichuan, China, 610071
- Rekrutierung
- Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 300020
- Rekrutierung
- Institute of Hematology and Hospital of Blood Disease
-
-
Yunnan
-
Kunming, Yunnan, China, 650032
- Rekrutierung
- First Affiliated Hospital of Kunming Medical University
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310002
- Rekrutierung
- The First Affiliated Hospital, Zhejiang University School of Medicinechengzhan
-
-
-
-
-
Deggendorf, Deutschland, 94469
- Rekrutierung
- Donauisar Klinikum Deggendorf Klinik Fur Onkologie Und Hamatologie
-
Frankfurt am Main, Deutschland, 60389
- Rekrutierung
- Centrum Fur Haematologie Und Onkologie Bethanien
-
Münster, Deutschland, 48153
- Rekrutierung
- Geho Munster
-
Straubing, Deutschland, 94315
- Rekrutierung
- Klinikum St Elisabeth Straubing Gmbh Mvz Klinikum Straubing Gmbh
-
-
-
-
-
Bordeaux, Frankreich, 33076
- Rekrutierung
- Centre de Lutte Contre Le Cancer Institut Bergonie
-
ClermontFerrand, Frankreich, 63100
- Rekrutierung
- Chu Clermont Ferrand Therapie Cellulaire and Hematolo
-
Le Mans, Frankreich, 72037
- Rekrutierung
- Centre Hospitalier Le Mans
-
Lille, Frankreich, 59000
- Rekrutierung
- Hopital Claude Huriez Chu Lille
-
Lyon, Frankreich, 69373
- Rekrutierung
- Centre Leon Berard
-
Montpellier, Frankreich, 34090
- Rekrutierung
- Chu Montpellier Hopital Saint Eloi
-
Toulouse, Frankreich, 31100
- Rekrutierung
- Iuc Toulouse Oncopole
-
-
-
-
-
Bologna, Italien, 40138
- Rekrutierung
- Irccs Azienda Ospedaliero Universitaria Bologna
-
Florence, Italien, 50134
- Rekrutierung
- Aou Careggi, Servizio Sanitario Toscana
-
Milan, Italien, 20132
- Rekrutierung
- Ospedale San Raffaele
-
Milan, Italien, 20162
- Rekrutierung
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
-
Padova, Italien, 35128
- Rekrutierung
- Azienda Ospedaliera Di Padova
-
Roma, Italien, 00168
- Rekrutierung
- Fondazione Policlinico Universitario Agostino Gemelli
-
-
-
-
British Columbia
-
Victoria, British Columbia, Kanada, V8R 6V5
- Rekrutierung
- Bc Cancer Victoria
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8V 5C2
- Rekrutierung
- Juravinski Cancer Centre
-
-
Quebec
-
Montreal, Quebec, Kanada, QC H3t 1E2
- Rekrutierung
- Jewish General Hospital
-
Montreal, Quebec, Kanada, H4J 1C5
- Rekrutierung
- Ciusss Nim Hscm
-
Québec, Quebec, Kanada, G1J 1Z4
- Rekrutierung
- Chu de Quebec Universite Laval, Hopital de Lenfant Jesus, Centre Integre de Cancerologie (Cic)
-
Sherbrooke, Quebec, Kanada, J1H 5N4
- Rekrutierung
- Ciusss de Lestrie Chus
-
-
-
-
-
Auckland, Neuseeland, 1023
- Rekrutierung
- Auckland City Hospital
-
Auckland, Neuseeland, 0622
- Rekrutierung
- North Shore Hospital
-
Christchurch, Neuseeland, 8011
- Rekrutierung
- Health New Zealand Canterbury
-
Dunedin, Neuseeland, 9016
- Rekrutierung
- Dunedin Hospital
-
Wellington, Neuseeland, 6021
- Rekrutierung
- Wellington Regional Hospital (Ccdhb)
-
-
-
-
-
Almere Stad, Niederlande, 1315 RA
- Rekrutierung
- Flevoziekenhuis
-
Dordrecht, Niederlande, 3318 AT
- Rekrutierung
- Albert Schweitzer Ziekenhuis
-
Sgravenhage, Niederlande, 2545 AA
- Rekrutierung
- Hagaziekenhuis
-
-
-
-
-
Brzozów, Polen, 36-200
- Rekrutierung
- Szpital Specjalist W Brzozowie,Podkarpacki Osrodek Onkologiczny
-
Katowice, Polen, 40-519
- Rekrutierung
- Pratia Onkologia Katowice
-
Krakow, Polen, 30-727
- Rekrutierung
- Pratia McM Krakow
-
Lublin, Polen, 20-090
- Rekrutierung
- Uniwersytecki Szpital Kliniczny Nr 4 W Lublinie
-
Wroclaw, Polen, 50-367
- Rekrutierung
- Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu
-
-
-
-
-
Bucharest, Rumänien, 30171
- Rekrutierung
- Coltea Clinical Hospital
-
Bucureti, Rumänien, 022328
- Rekrutierung
- Institutul Clinic Fundeni
-
ClujNapoca, Rumänien, 400015
- Rekrutierung
- Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca
-
-
-
-
-
Stockholm, Schweden, 171 76
- Rekrutierung
- Karolinska Universitetssjukhuset Solna
-
-
-
-
-
Granada, Spanien, 18014
- Rekrutierung
- Hospital Universitario Virgen de Las Nieves
-
Madrid, Spanien, 28041
- Rekrutierung
- Hospital Universitario 12 de Octubre
-
Majadahonda, Spanien, 28222
- Rekrutierung
- Hospital Universitario Puerta de Hierro Majadahonda
-
Murcia, Spanien, 30120
- Rekrutierung
- Hospital Clinico Universitario Virgen de La Arrixaca
-
-
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, Südkorea, 13620
- Rekrutierung
- Seoul National University Bundang Hospital
-
-
Seoul Teugbyeolsi
-
SeochoGu, Seoul Teugbyeolsi, Südkorea, 06591
- Rekrutierung
- The Catholic University of Korea, Seoul St Marys Hospital
-
SeodaemunGu, Seoul Teugbyeolsi, Südkorea, 03722
- Rekrutierung
- Severance Hospital Yonsei University Health System
-
Seoul, Seoul Teugbyeolsi, Südkorea, 03080
- Rekrutierung
- Seoul National University Hospital
-
SongpaGu, Seoul Teugbyeolsi, Südkorea, 05505
- Rekrutierung
- Asan Medical Center
-
-
-
-
-
Brno, Tschechien, 625 00
- Rekrutierung
- Fakultni Nemocnice Brno
-
Hradec Králové, Tschechien, 500 03
- Rekrutierung
- Fakultni Nemocnice Hradec Kralove
-
Olomouc, Tschechien, 77900
- Rekrutierung
- Fakultni Nemocnice Olomouc
-
Ostrava, Tschechien, 708 00
- Rekrutierung
- Fakultni Nemocnice Ostrava
-
PLZE, Tschechien, 323 00
- Rekrutierung
- Fakultni Nemocnice Plzen
-
Prague, Tschechien, 10000
- Rekrutierung
- Vseobecna Fakultni Nemocnice V Praze
-
-
-
-
California
-
Duarte, California, Vereinigte Staaten, 91010-3012
- Rekrutierung
- City of Hope National Medical Center
-
Orange, California, Vereinigte Staaten, 92868-3201
- Rekrutierung
- Chao Family Comprehensive Cancer Center
-
Palo Alto, California, Vereinigte Staaten, 94304-2205
- Rekrutierung
- Stanford Cancer Institute
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80012-5405
- Rekrutierung
- Rocky Mountain Cancer Centers (Williams) Usor
-
-
Florida
-
Jacksonville, Florida, Vereinigte Staaten, 32224-1865
- Rekrutierung
- Mayo Clinic Jacksonville
-
Miami, Florida, Vereinigte Staaten, 33140
- Rekrutierung
- Mount Sinai Medical Center Braman Comprehensive Cancer Center
-
Tampa, Florida, Vereinigte Staaten, 33612-9496
- Rekrutierung
- Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Rekrutierung
- Northwestern University
-
Zion, Illinois, Vereinigte Staaten, 60099-2676
- Rekrutierung
- Midwestern Regional Medical Center
-
-
Louisiana
-
New Orleans, Louisiana, Vereinigte Staaten, 70121-2429
- Rekrutierung
- Ochsner Clinic Foundation
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02215-5418
- Rekrutierung
- Dana Farber Cancer Institute
-
-
Minnesota
-
Rochester, Minnesota, Vereinigte Staaten, 55905-0001
- Rekrutierung
- Mayo Clinic Rochester
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68198
- Rekrutierung
- University of Nebraska Medical Center
-
-
New York
-
New York, New York, Vereinigte Staaten, 10032
- Rekrutierung
- Columbia University Medical Center
-
-
North Carolina
-
Charlotte, North Carolina, Vereinigte Staaten, 28204-2990
- Rekrutierung
- Atrium Health Levine Cancer Institute (Lci)
-
Durham, North Carolina, Vereinigte Staaten, 27705-3976
- Rekrutierung
- Duke University Medical Center
-
-
Oregon
-
Eugene, Oregon, Vereinigte Staaten, 97401
- Rekrutierung
- Oncology Associates of Oregon Willamette Valley Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15232-1309
- Rekrutierung
- Upmc Hillman Cancer Center(Univ of Pittsburgh)
-
-
Texas
-
Tyler, Texas, Vereinigte Staaten, 75702-7522
- Rekrutierung
- Texas Oncology Tyler
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84112-5550
- Rekrutierung
- Huntsman Cancer Institute
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98109-4433
- Rekrutierung
- Fred Hutchinson Cancer Research Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53226-3522
- Rekrutierung
- Medical College of Wisconsin
-
-
-
-
-
Birmingham, Vereinigtes Königreich, B15 2TH
- Rekrutierung
- Queen Elizabeth Hospital
-
Bournemouth, Vereinigtes Königreich, BH7 7DW
- Rekrutierung
- University Hospitals Dorset Royal Bournemouth Hospital
-
Leeds, Vereinigtes Königreich, LS9 7TF
- Rekrutierung
- St Jamess University Hospital
-
London, Vereinigtes Königreich, SE5 9RS
- Rekrutierung
- Kings College Hospital
-
Norwich, Vereinigtes Königreich, NR4 7UY
- Rekrutierung
- Norfolk and Norwich University Hospitals Nhs Foundation Trust
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Treatment-naïve (TN) adults with confirmed diagnosis of CLL which requires treatment
- Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2
- Measurable disease by Computer Tomography/Magnetic Resonance Imaging
- Adequate bone marrow and organ function
Exclusion Criteria:
- Previous systemic treatment for CLL
- Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation
- Known central nervous system involvement
- History of confirmed progressive multifocal leukoencephalopathy (PML)
- Uncontrolled hypertension or clinically significant cardiovascular disease
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Arm A: Sonrotoclax plus Zanubrutinib
Participants will receive sonrotoclax and zanubrutinib for a fixed duration followed by observation. |
Administered orally.
Andere Namen:
Administered orally.
Andere Namen:
|
|
Aktiver Komparator: Arm B: Venetoclax plus Acalabrutinib
Participants will receive venetoclax and acalabrutinib for a fixed duration followed by observation. |
Administered orally.
Andere Namen:
Administered orally.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Progression-Free Survival (PFS) as Determined by Independent Review Committee (IRC)
Zeitfenster: Up to approximately 70 months
|
PFS is defined as the time from the date of randomization to the date of disease progression as determined by IRC or death due to any cause, whichever occurs first. |
Up to approximately 70 months
|
|
Rate of Undetectable Minimal Residual Disease at < 10^-4 sensitivity (uMRD4)
Zeitfenster: Up to approximately 16 months
|
Rate of uMRD4 is defined as the percentage of participants that achieved uMRD4 measured in both peripheral blood (PB) and bone marrow aspirate (BMA) at the post-treatment follow-up visit (PTFU1) based on next generation sequencing (NGS). |
Up to approximately 16 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
PFS in High-Risk Participants
Zeitfenster: Up to approximately 70 months
|
PFS is defined as the time from the date of randomization to the date of disease progression as determined by IRC or death due to any cause, whichever occurs first. |
Up to approximately 70 months
|
|
Overall Survival (OS)
Zeitfenster: Up to approximately 70 months
|
OS is defined as the time from the date of randomization to the date of death due to any cause. |
Up to approximately 70 months
|
|
Overall Response Rate (ORR) as Determined by IRC
Zeitfenster: Up to approximately 70 months
|
ORR is defined as the percentage of participants with a complete response (CR), complete response with incomplete hematopoietic recovery (CRi), nodal partial response (nPR), or partial response (PR), before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier), as assessed by IRC. |
Up to approximately 70 months
|
|
Rate of Undetectable Minimal Residual Disease at < 10^-5 sensitivity (uMRD5)
Zeitfenster: Up to approximately 16 months
|
Rate of uMRD5 is defined as the percentage of participants who achieved uMRD5 measured in both PB and BMA at the PTFU1 Visit based on NGS, before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier). |
Up to approximately 16 months
|
|
Number of Participants with Adverse Events
Zeitfenster: Up to approximately 70 months
|
Number of participants with treatment-emergent adverse events (TEAEs), adverse events of clinical interest, and serious adverse events (SAEs), including laboratory values, vital signs, and physical examination findings. |
Up to approximately 70 months
|
|
PFS Determined by Investigator Assessment
Zeitfenster: Up to approximately 70 months
|
PFS is defined as the time from the date of randomization to the date of disease progression as determined by investigator or death due to any cause, whichever occurs first. |
Up to approximately 70 months
|
|
Complete Response Rate (CRR) by IRC and Investigator Assessment
Zeitfenster: Up to approximately 70 months
|
CRR is defined as the percentage of participants with a CR or CRi before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier). |
Up to approximately 70 months
|
|
ORR Determined by Investigator Assessment
Zeitfenster: Up to approximately 70 months
|
ORR is defined as the percentage of participants with a complete response or partial response, before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier), as assessed by investigator. |
Up to approximately 70 months
|
|
Duration of Response (DOR)
Zeitfenster: Up to approximately 70 months
|
Duration of response (determined by both IRC and investigator assessment) is defined as the time from the first qualifying response (CR, CRi, nPR, or PR) until CLL progression or death. DOR analysis will only include responders. |
Up to approximately 70 months
|
|
Time to Next Treatment (TTNT)
Zeitfenster: Up to approximately 70 months
|
TTNT is defined as the time from randomization to the start of the next treatment for CLL. |
Up to approximately 70 months
|
|
Change from Baseline in Score on European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL)-409 Questionnaire
Zeitfenster: At baseline and up to approximately 70 months
|
Patient-reported symptoms of global health status (GHS), role functioning, and physical functioning, symptom burden and physical condition/fatigue will be measured using the European Organization for Research and Treatment of Cancer quality of life questionnaire EORTC IL-409 (an itemized version of [EORTC] quality of life questionnaire core 30 [QLQ-C30] and its CLL module CLL17). The EORTC-IL-409 consists of 17 questions answered on a 4-point scale where 1 = Not at all (best) to 4 = Very Much (worst) and 2 global health questions answered on a 7-point scale where 1 = Very poor (worst) to 7 = Excellent (best). Higher scores in GHS and functional scales and lower scores in symptom scales indicate better quality of life. |
At baseline and up to approximately 70 months
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Study Director, BeOne Medicines
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Pathologische Prozesse
- Neubildungen
- Chronische Erkrankung
- Krankheitsattribute
- Erkrankungen des Immunsystems
- Neubildungen nach histologischem Typ
- Hämatologische Erkrankungen
- Lymphatische Erkrankungen
- Lymphoproliferative Erkrankungen
- Immunproliferative Erkrankungen
- Leukämie, B-Zell
- Leukämie, lymphatisch
- Leukämie
- Pathologische Zustände, Anzeichen und Symptome
- Hämische und lymphatische Krankheiten
- Leukämie, lymphozytär, chronisch, B-Zell
- Zanubrutinib
- Venetoklax
- Acalabrutinib
Andere Studien-ID-Nummern
- BGB-11417-304
- 2025-524366-21-00 (Ctis)
- 2025 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.
BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.
Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
IPD-Sharing-Zeitrahmen
See plan description
IPD-Sharing-Zugriffskriterien
See plan description
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- CSR
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .